Product Description
Eslicarbazepine is used in combination with other medications to control focal (partial) seizures (seizures that involve only one part of the brain). Eslicarbazepine is in a class of medications called anticonvulsants. It works by decreasing abnormal excitement in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a614032.html)
Mechanisms of Action: Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bulgaria | Canada | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Malta | Netherlands | Norway | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: Bial
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, China, France, Germany, Israel, Italy, Portugal, Spain, Sweden, United Kingdom
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Epilepsy|Stroke
Phase 1: Seizures
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CTR20243621 | P1 |
Completed |
Seizures |
2024-11-03 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| BIA-2093-213 | P2 |
Completed |
Stroke|Epilepsy |
2023-09-11 |
2024-09-20 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/24/2024 |
News Article |
CRC Expands Medical Leadership Team with Appointment of Accomplished Medical Directors |
|
07/12/2024 |
News Article |
Central Nervous System (CNS) Stimulant Drugs Market size is set to grow by USD 6.48 billion from 2023-2027, Rise in incidence of CNS disorders boost the market, Technavio |
|
07/03/2024 |
News Article |
McGill, industry, CQDM and Brain Canada collaborate for drug discovery |
|
06/18/2024 |
News Article |
PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team |